1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Regulation

HeartWare VAD Battery Alert Tagged As Class I Recall

An FDA recall notice states that HeartWare, which is being acquired by Medtronic, has recalled almost 19,000 ventricular-assist device batteries due to a risk of losing charge prematurely.

Days after Medtronic PLC announced it was buying HeartWare International Inc. for more than a billion dollars, FDA tagged an alert for batteries used in the company's HVAD system as a class I recall

. The agency says the batteries could lose charge prematurely due to faulty cells. (See Also see "Medtronic Ups Its Heart-Failure Competitive Strength With HeartWare Buy" - Medtech Insight,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

FDLI: Clinical Labs Face Uncertainty After Texas Court’s LDT Ruling

 
• By Elizabeth Orr

A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.